Summary
CYP2C9 substrates are compounds that are metabolized by CYP2C9 (a cytochrome P450 enzyme), but do not necessarily affect its activity.
In the presence of CYP2C9 inhibitors or inducers, the metabolism of CYP2C9 substrates can be affected.
The table below outlines some of the most common or clinically relevant CYP2C9 substrates.[1][2][3] Importantly, this list is not exhaustive.
| CYP2C9 Substrates |
|---|
| Candesartan |
| Celecoxib |
| Cyclophosphamide* |
| Diclofenac |
| Fluoxetine |
| Fluvastatin |
| Gliclazide |
| Ibuprofen |
| Irbesartan |
| Losartan |
| Meloxicam |
| Naproxen |
| Phenytoin |
| Rosuvastatin |
| Tamoxifen* |
| Valproic acid |
| Valsartan |
| Warfarin |
* Prodrugs are indicated with an asterisk
References
- ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
- ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
- ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)